Target intelligence / Profile preview

Mitochondrially encoded NADH:ubiquinone oxidoreductase subunit 5 (MT-ND5)

Target
MT-ND5
Molecular classification
Enzyme, Mitochondrial respiratory chain component, Oxidoreductase (Complex I subunit)
01

Overview

Mitochondrially encoded NADH:ubiquinone oxidoreductase subunit 5 (MT-ND5) is a core protein component of complex I in the mitochondrial respiratory chain, located in the inner mitochondrial membrane[1][5]. MT-ND5 is responsible for coupling NADH oxidation to proton translocation across the membrane, facilitating ATP synthesis via oxidative phosphorylation[3][5]. Mutations in the MT-ND5 gene impair electron transport, reduce ATP production, alter mitochondrial membrane potential, and are implicated in a broad spectrum of mitochondrial disorders—including MELAS, Leigh syndrome, and Leber hereditary optic neuropathy. MT-ND5 is considered essential for proper mitochondrial energy metabolism, and genetic variations are important biomarkers for mitochondrial and neurodegenerative diseases[1][3][5].

Other names
NADH-ubiquinone oxidoreductase chain 5MTND5NADH5ND5NADH dehydrogenase subunit 5complex I ND5 subunit
02

Mechanism of action

Inhibition of electron transfer from NADH to ubiquinone, leading to reduction in ATP production and increased production of reactive oxygen species (with complex I inhibitors like rotenone)[2]

03

Biological functions

Mitochondrial electron transport (NADH to ubiquinone)Proton translocation across inner mitochondrial membraneATP synthesis (part of oxidative phosphorylation)
04

Disease associations

Mitochondrial disease (MELAS syndrome)Leigh syndromeLeber hereditary optic neuropathy (LHON)CardiomyopathyNeurodegenerative diseaseOther mitochondrial-related disorders[1][3][5]
05

Safety considerations

Mutations disrupt cellular energy production, particularly impacting high-energy demanding organs such as brain, muscle, heart, and kidney, potentially causing multi-systemic disease manifestations[1][3]
06

Interacting drugs

Rotenone (inhibitor of complex I, used experimentally)[2]
07

Biomarkers

MT-ND5 mutations (used in diagnosis of MELAS, Leigh syndrome, and other mitochondrial diseases)[1][3][5]

Beyond the preview

Go deeper on Mitochondrially encoded NADH:ubiquinone oxidoreductase subunit 5 (MT-ND5).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrially encoded NADH:ubiquinone oxidoreductase subunit 5 (MT-ND5).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call